Oncotarget

Research Papers:

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia

Annalisa Astolfi _, Francesca Vendemini, Milena Urbini, Fraia Melchionda, Riccardo Masetti, Monica Franzoni, Virginia Libri, Salvatore Serravalle, Marco Togni, Giuseppina Paone, Luca Montemurro, Daniela Bressanin, Francesca Chiarini, Alberto M Martelli, Roberto Tonelli and Andrea Pession

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:120-130. https://doi.org/10.18632/oncotarget.1337

Metrics: PDF 1917 views  |   HTML 2028 views  |   ?  


Abstract

Annalisa Astolfi1,2, Francesca Vendemini2, Milena Urbini1,2, Fraia Melchionda2, Riccardo Masetti2, Monica Franzoni2, Virginia Libri2, Salvatore Serravalle2, Marco Togni2, Giuseppina Paone2, Luca Montemurro2,Daniela Bressanin3, Francesca Chiarini4, Alberto M. Martelli3, Roberto Tonelli5, Andrea Pession1,2

1 “Giorgio Prodi” Cancer Research Center, University of Bologna, Bologna, Italy;

2 Pediatric Oncology and Hematology Unit “Lalla Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;

3 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy;

4 Institute of Molecular Genetics, National Research Council-IOR, Bologna, Italy;

5 Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Correspondence:

Riccardo Masetti, email:

Keywords: pediatric T-ALL, MYCN, peptide nucleic acid, TAL1

Received: August 28, 2013 Accepted: September 27, 2013 Published: September 29, 2013

Abstract

MYCN is an oncogene frequently overexpressed in pediatric solid tumors whereas few evidences suggest his involvement in the pathogenesis of haematologic malignancies. Here we show that MYCN is overexpressed in a relevant proportion (40 to 50%) of adult and pediatric T-cell acute lymphoblastic leukemias (T-ALL). Focusing on pediatric T-ALL, MYCN-expressing samples were found almost exclusively in the TAL1-positive subgroup. Moreover, TAL1 knockdown in T-ALL cell lines resulted in a reduction of MYCN expression, and TAL1 directly binds to MYCN promoter region, suggesting that TAL1 pathway activation could sustain the up-regulation of MYCN. The role of MYCN in T-ALL was investigated by peptide nucleic acid (PNA-MYCN)-mediated transcriptional silencing of MYCN and by siRNAs. MYCN knockdown in T-ALL cell lines resulted in a reduction of cell viability, up to 50%, while no effect was elicited with a mismatch PNA. The inhibitory effect of PNA-MYCN on cell viability was due to a significant increase in apoptosis. PNA-MYCN treatment in pediatric T-ALL samples reduced cell viability of leukemic cells from patients with high MYCN expression, while no effect was obtained in MYCN-negative blast cells. These results showed that MYCN is frequently overexpressed in pediatric T-ALL and suggested his role as a candidate for molecularly-directed therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1337